Skip NavigationSkip to Content
Return Return to Search Results

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics

  1. Author:
    Hursey, M.
    Newton, D. L.
    Hansen, H. J.
    Ruby, D.
    Goldenberg, D. M.
    Rybak, S. M.

  2. Author Address

    NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA Rybak SM NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA
    1. Year: 2002
  2. Journal: Leukemia & Lymphoma
    1. 43
    2. 5
    3. Pages: 953-959
  4. Type of Article: Review
  1. Abstract:

    Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA-damaging chemotherapeutics. A second generation construct with an improved recombinant cytotoxic RNAse is described. Targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin- containing immunoconjugates.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel